Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy Virtual 2020 | An update of COVID-19 in the hemonc clinical setting in Spain

Paula Rodríguez-Otero • 14 May 2020
COMy Virtual 2020
Multiple Myeloma

Here, Paula Rodríguez-Otero, MD, PhD, University of Navarra, Pamplona, Spain, shares her experience of the impact of COVID-19 in the hematological oncology clinical setting in Spain.
This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Paula Rodríguez-Otero

Ide-cel versus standard regimens in TCE R/R multiple myeloma: updated analysis of KarMMa-3 4:04
Ide-cel versus standard regimens in TCE R/R multiple myeloma: updated analysis of KarMMa-3
Paula Rodríguez-Otero • 15 Dec 2023
Investigating linvoseltamab monotherapy in SMM: the LINKER-SMM1 trial 1:56
Investigating linvoseltamab monotherapy in SMM: the LINKER-SMM1 trial
Paula Rodríguez-Otero • 15 Dec 2023
MonumenTAL-1: incidence of severe infections & parameters of humoral immunity with talquetamab 1:55
MonumenTAL-1: incidence of severe infections & parameters of humoral immunity with talquetamab
Paula Rodríguez-Otero • 15 Jun 2023
KarMMa-3: QoL of patients with TCE R/R myeloma treated with ide-cel vs standard regimens 1:29
KarMMa-3: QoL of patients with TCE R/R myeloma treated with ide-cel vs standard regimens
Paula Rodríguez-Otero • 15 Jun 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals